Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation

Cytokine and Growth Factor Reviews

Volumn 19, Issue 1, 2008, Pages 53-63

  Mohty, Mohamad ^a   Gaugler, Béatrice ^b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Cytokines; DCs; GVHD

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CORTICOSTEROID; CYCLOSPORIN A; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; RAPAMYCIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; DENDRITIC CELL; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; LYMPH NODE IRRADIATION; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACUTE DISEASE; ANIMALS; DENDRITIC CELLS; GRAFT VS HOST DISEASE; HUMANS; INTERLEUKIN-1; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39049093664     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2007.10.010     Document Type: Article

References (88)

1. Billingham R.E. The biology of graft-versus-host reactions. Harvey Lect 62 (1966) 21-78
2. Sackstein R. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant 12 (2006) 2-8
3. Holler E., Kolb H.J., Moller A., Kempeni J., Liesenfeld S., Pechumer H., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75 (1990) 1011-1016
4. Ferrara J.L., and Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 43 (2006) 3-10
5. Holler E., Kolb H.J., Mittermuller J., Kaul M., Ledderose G., Duell T., et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86 (1995) 890-899
6. Beelen D.W., Elmaagacli A., Muller K.D., Hirche H., and Schaefer U.W. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 93 (1999) 3267-3275
7. Holler E., Rogler G., Herfarth H., Brenmoehl J., Wild P.J., Hahn J., et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 104 (2004) 889-894
8. Holler E., Rogler G., Brenmoehl J., Hahn J., Herfarth H., Greinix H., et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 107 (2006) 4189-4193
9. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
10. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
11. Ogura Y., Lala S., Xin W., Smith E., Dowds T.A., Chen F.F., et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 52 (2003) 1591-1597
12. Ferrara J.L., Levy R., and Chao N.J. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 5 (1999) 347-356
13. Flowers M.E., Kansu E., and Sullivan K.M. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 13 (1999) 1091-1112
14. Balduzzi A., Gooley T., Anasetti C., Sanders J.E., Martin P.J., Petersdorf E.W., et al. Unrelated donor marrow transplantation in children. Blood 86 (1995) 3247-3256
15. Petersdorf E.W., Mickelson E.M., Anasetti C., Martin P.J., Woolfrey A.E., and Hansen J.A. Effect of HLA mismatches on the outcome of hematopoietic transplants. Curr Opin Immunol 11 (1999) 521-526
16. Sullivan K.M., Deeg H.J., Sanders J., Klosterman A., Amos D., Shulman H., et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 67 (1986) 1172-1175
17. Goker H., Haznedaroglu I.C., and Chao N.J. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 29 (2001) 259-277
18. Shlomchik W.D., Couzens M.S., Tang C.B., McNiff J., Robert M.E., Liu J., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 (1999) 412-415
19. Teshima T., Ordemann R., Reddy P., Gagin S., Liu C., Cooke K.R., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8 (2002) 575-581
20. Matte C.C., Liu J., Cormier J., Anderson B.E., Athanasiadis I., Jain D., et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 10 (2004) 987-992
21. Mapara M.Y., Kim Y.M., Wang S.P., Bronson R., Sachs D.H., and Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100 (2002) 1903-1909
22. Reddy P., Maeda Y., Liu C., Krijanovski O.I., Korngold R., and Ferrara J.L. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 11 (2005) 1244-1249
23. Mapara M.Y., Kim Y.M., Marx J., and Sykes M. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation 76 (2003) 297-305
24. Ordemann R., Hutchinson R., Friedman J., Burakoff S.J., Reddy P., Duffner U., et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest 109 (2002) 1249-1256
25. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
26. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
27. van Kooyk Y., and Geijtenbeek T.B. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 3 (2003) 697-709
28. Sallusto F., and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179 (1994) 1109-1118
29. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
30. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23 (2005) 275-306
31. Kuwana M., Kaburaki J., Wright T.M., Kawakami Y., and Ikeda Y. Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 31 (2001) 2547-2557
32. Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y.J., et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4 + CD25+ regulatory T cells. J Immunol 173 (2004) 4433-4442
33. Gilliet M., and Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195 (2002) 695-704
34. Colonna M., Trinchieri G., and Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 5 (2004) 1219-1226
35. Martin P., Del Hoyo G.M., Anjuere F., Arias C.F., Vargas H.H., Fernandez L.A., et al. Characterization of a new subpopulation of mouse CD8alpha+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 100 (2002) 383-390
36. Bilsborough J., George T.C., Norment A., and Viney J.L. Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 108 (2003) 481-492
37. de Heer H.J., Hammad H., Soullie T., Hijdra D., Vos N., Willart M.A., et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 200 (2004) 89-98
38. Mellor A.L., Baban B., Chandler P., Marshall B., Jhaver K., Hansen A., et al. Cutting edge: induced indoleamine-2,3-dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171 (2003) 1652-1655
39. Fallarino F., Asselin-Paturel C., Vacca C., Bianchi R., Gizzi S., Fioretti M.C., et al. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 173 (2004) 3748-3754
40. Salio M., Palmowski M.J., Atzberger A., Hermans I.F., and Cerundolo V. CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. J Exp Med 199 (2004) 567-579
41. Schlecht G., Garcia S., Escriou N., Freitas A.A., Leclerc C., and Dadaglio G. Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood 104 (2004) 1808-1815
42. Ochando J.C., Homma C., Yang Y., Hidalgo A., Garin A., Tacke F., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 7 (2006) 652-662
43. Benitez-Ribas D., Adema G.J., Winkels G., Klasen I.S., Punt C.J., Figdor C.G., et al. Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake. J Exp Med 203 (2006) 1629-1635
44. Waller E.K., Rosenthal H., Jones T.W., Peel J., Lonial S., Langston A., et al. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 97 (2001) 2948-2956
45. Arpinati M., Green C.L., Heimfeld S., Heuser J.E., and Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95 (2000) 2484-2490
46. Fagnoni F.F., Oliviero B., Giorgiani G., De Stefano P., Dehò A., Zibera C., et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood 104 (2004) 281-289
47. Chklovskaia E., Nowbakht P., Nissen C., Gratwohl A., Bargetzi M., and Wodnar-Filipowicz A. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand. Blood 103 (2004) 3860-3868
48. Mohty M., Blaise D., Faucher C., Bardou V.J., Gastaut J.A., Viens P., et al. Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia 19 (2005) 1-6
49. Reddy V., Iturraspe J.A., Tzolas A.C., Meier-Kriesche H.U., Schold J., and Wingard J.R. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood 103 (2004) 4330-4335
50. Vakkila J., Thomson A.W., Hovi L., Vettenranta K., and Saarinen-Pihkala U.M. Circulating dendritic cell subset levels after allogeneic stem cell transplantation in children correlate with time post transplant and severity of acute graft-versus-host disease. Bone Marrow Transplant 35 (2005) 501-507
51. Arpinati M., Chirumbolo G., Urbini B., Bonifazi F., Bandini G., Saunthararajah Y., et al. Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10 (2004) 106-115
52. Kitawaki T., Kadowaki N., Ishikawa T., Ichinohe T., and Uchiyama T. Compromised recovery of natural interferon-alpha/beta-producing cells after allogeneic hematopoietic stem cell transplantation complicated by acute graft-versus-host disease and glucocorticoid administration. Bone Marrow Transplant 32 (2003) 187-194
53. Clark F.J., Freeman L., Dzionek A., Schmitz J., McMullan D., Simpson P., et al. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation 75 (2003) 221-225
54. Collin M.P., Hart D.N., Jackson G.H., Cook G., Cavet J., Mackinnon S., et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med 203 (2006) 27-33
55. Vanbervliet B., Bendriss-Vermare N., Massacrier C., Homey B., de Bouteiller O., Brière F., et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 198 (2003) 823-830
56. Farkas L., Beiske K., Lund-Johansen F., Brandtzaeg P., and Jahnsen F.L. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 159 (2001) 237-243
57. Wollenberg A., Wagner M., Günther S., Towarowski A., Tuma E., Moderer M., et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 119 (2002) 1096-1102
58. Bangert C., Friedl J., Stary G., Stingl G., and Kopp T. Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease?. J Invest Dermatol 121 (2003) 1409-1418
59. Gilliet M., Conrad C., Geiges M., Cozzio A., Thürlimann W., Burg G., et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 140 (2004) 1490-1495
60. Cederblad B., Blomberg S., Vallin H., Perers A., Alm G.V., and Ronnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J Autoimmun 11 (1998) 465-470
61. Blomberg S., Eloranta M.L., Cederblad B., Nordlin K., Alm G.V., and Ronnblom L. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 10 (2001) 484-490
62. Vallin H., Perers A., Alm G.V., and Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 163 (1999) 6306-6313
63. Blanco P., Palucka A.K., Gill M., Pascual V., and Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294 (2001) 1540-1543
64. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., and Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19 (2003) 225-234
65. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202 (2005) 135-143
66. Gottenberg J.E., Cagnard N., Lucchesi C., Letourneur F., Mistou S., Lazure T., et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 103 (2006) 2770-2775
67. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., et al. Reciprocal control of T helper cell and dendritic cell differentiation [see comments]. Science 283 (1999) 1183-1186
68. Cooke K.R., Gerbitz A., Crawford J.M., Teshima T., Hill G.R., Tesolin A., et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 107 (2001) 1581-1589
69. Hattori K., Hirano T., Miyajima H., Yamakawa N., Tateno M., Oshimi K., et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 91 (1998) 4051-4055
70. Cooke K.R., Hill G.R., Gerbitz A., Kobzik L., Martin T.R., Crawford J.M., et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 70 (2000) 272-279
71. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 (2000) 121-127
72. Laster S.M., Wood J.G., and Gooding L.R. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 141 (1988) 2629-2634
73. Abhyankar S., Gilliland D.G., and Ferrara J.L. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 56 (1993) 1518-1523
74. Atkinson K., Matias C., Guiffre A., Seymour R., Cooley M., Biggs J., et al. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 77 (1991) 1376-1382
75. Hill G.R., Teshima T., Gerbitz A., Pan L., Cooke K.R., Brinson Y.S., et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 104 (1999) 459-467
76. Antin J.H., Weisdorf D., Neuberg D., Nicklow R., Clouthier S., Lee S.J., et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100 (2002) 3479-3482
77. Langrehr J.M., Murase N., Markus P.M., Cai X., Neuhaus P., Schraut W., et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 90 (1992) 679-683
78. Krenger W., Falzarano G., Delmonte Jr. J., Snyder K.M., Byon J.C., and Ferrara J.L. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 88 (1996) 1113-1121
79. Mohty M., Blaise D., Faucher C., Vey N., Bouabdallah R., Stoppa A.M., et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 106 (2005) 4407-4411
80. Wagner H., and Bauer S. All is not Toll: new pathways in DNA recognition. J Exp Med 203 (2006) 265-268
81. Granucci F., Foti M., and Ricciardi-Castagnoli P. Dendritic cell biology. Adv Immunol 88 (2005) 193-233
82. Inohara N., Ogura Y., and Nunez G. Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr Opin Microbiol 5 (2002) 76-80
83. Elmaagacli A.H., Koldehoff M., Hindahl H., Steckel N.K., Trenschel R., Peceny R., et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation 81 (2006) 247-254
84. Hara M., Kingsley C.I., Niimi M., Read S., Turvey S.E., Bushell A.R., et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 166 (2001) 3789-3796
85. Baker K.S., Roncarolo M.G., Peters C., Bigler M., DeFor T., and Blazar B.R. High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths. Bone Marrow Transplant 23 (1999) 1123-1129
86. Lin M.T., Storer B., Martin P.J., Tseng L.H., Gooley T., Chen P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349 (2003) 2201-2210
87. Hempel L., Korholz D., Nussbaum P., Bonig H., Burdach S., and Zintl F. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant 20 (1997) 365-368
88. Blazar B.R., Taylor P.A., Panoskaltsis-Mortari A., Narula S.K., Smith S.R., Roncarolo M.G., et al. Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease. Transplantation 66 (1998) 1220-1229